With Little Remaining Unmet Need for Injectable Biologics :

Despite the increased efficacy of BMS’ Sotyktu over Amgen’s Otezla, dermatologists continue to express a desire for additional oral agents that bring...

Related Keywords

Pennsylvania , United States , Janssen Tremfya , Eli Lilly Taltz , Abbvie Skyrizi , Janssen Stelara , Novarti Cosentyx , Dermatologics Siliq , Amgen Otezla , Amgen Enbrel , Abbvie Humira , Janssen Remicade , Sun Pharma Ilumya , Twitter , Linkedin , Spherix Network , Eli Lilly , Ortho Dermatologics , Sun Pharma , Spherix Global Insight Realtime Dynamix , Realtime Dynamix , Plaque Psoriasis , Time Dynamix , Global Insights , Spherix Global Insights , Spherix Global Insight , Psoriasis , Ermatology , Market Research , Pharmaceuticals , So , Biologic , Humira , Abbvie , Amgen , Janssen , Il 17 ,